---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107447"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:43:58.071992+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MetaVia reports Q3 net loss $3.4M, cash $14.3M; DA-1726 48mg cohort data due by year-end

## Summary
- Net loss of $3.4M ($0.14 per share) vs $5.7M ($0.55) in Q3 2024; cash $14.3M expected to fund into 2026.
- R&D expenses fell to $1.9M from $4.5M YoY; total operating expenses $3.5M.
- Dosed first patient in 8-week 48mg MAD cohort of DA-1726 for obesity; top-line data expected by year-end 2025.
- Phase 1 DA-1726 data: 6.3% mean weight loss, 3.9-inch waist reduction, PK supports once-weekly dosing.
- Vanoglipel (DA-1241) Phase 2a showed reductions in liver fat, inflammation, fibrosis; end-of-Phase 2 FDA meeting H1 2026.

## SEC filing metadata
- accession: 0001104659-25-107447
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465925107447/0001104659-25-107447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465925107447/mtva-20251106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107447
- JSON: https://secwatch.observer/filing/0001104659-25-107447.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.